Computer grading of lung disease severity in patients with lymphangioleiomyomatosis referred for transplantation

Angelo M. Taveira-DaSilva¹, Vissaagan Gopalakrishnan¹, Jianhua Yao², Marcus Y. Chen³, Patricia Julien-Williams¹, Amanda M. Jones¹, Gustavo Pacheco-Rodriguez¹ and Joel Moss¹*

Abstract

Objectives: Lymphangioleiomyomatosis (LAM) patients with severe lung disease may be considered for lung transplantation. Clinical, physiologic, and quality of life data are usually employed for referral. The aim of this study was to determine whether computed tomographic measurement of lung volume occupied by cysts (cyst score) complemented clinical and physiologic data in supporting referral for transplantation.

Methods: Forty-one patients were studied. Pre-referral clinical data, pulmonary function tests, exercise testing, and high-resolution computed tomography (HRCT) scans were obtained. From HRCT, a computer-aided diagnostic program was employed to calculate cyst scores. These data were compared to those of 41 age-matched LAM patients not referred for lung transplantation.

Results: Cyst score, and % predicted FEV₁ and DLCO were respectively, 48.1 ± 9.4%, 36.5 ± 9.1%, and 35.0 ± 10.7%. For the control group, cyst score, FEV₁, and DLCO were respectively, 14.8 ± 8.3%, 77.2 ± 20.3%, and 66.7 ± 19.3%. Cyst score values showed a normal distribution. However, the frequency distribution of FEV₁ was skewed to the right while the distribution of DLCO was bimodal. Correlations between cyst score and FEV₁ and DLCO for the study group were respectively, r = −0.319 and r = −0.421.

Conclusions: LAM patients referred for lung transplantation had nearly 50% of lungs occupied by cysts. Correlations between cyst score and FEV₁ or DLCO were weak; as shown previously, DLCO was better related to cyst number while FEV₁ had a better association with cyst size. Given its normal distribution, cyst score measurements may assist in evaluation of pre-transplant severity of lung disease before referral for transplantation.

Keywords: Lymphangioleiomyomatosis (LAM), Lung transplant, Cystic lung disease, High resolution computed tomography (HRCT)

Background

Lymphangioleiomyomatosis (LAM), a multi-system disease that primarily affects women, is characterized by cystic lung destruction, lymphatic involvement (e.g., chylous effusions, lymphangioleiomyomas), and abdominal tumors, e.g., angiomyolipomas (AML) [1–3]. LAM occurs sporadically or in association with Tuberous Sclerosis Complex (TSC), an inherited disorder associated with seizures, cognitive impairment, and dermatological manifestations [4]. LAM lung destruction results from the presence of abnormal LAM cells, which have both melanocyte and smooth muscle cell characteristics and harbor mutations of the TSC1 or TSC2 genes [5–7].

*Correspondence: mossj@nhlbi.nih.gov

1 Pulmonary Branch, NHLBI, NIH, Building 10, Room 6D05, MSC 1590, Bethesda, MD 20892-1590, USA
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
loss of function of two proteins, hamartin and tuberin, encoded respectively by TSC1 and TSC2 genes, results in activation of the mechanistic Target of Rapamycin (mTOR) signaling pathway, which is responsible for cell growth, size, and survival [8].

The course of lung disease in LAM is highly variable but may result in progressive loss of lung function, severe exercise limitation, and respiratory failure, requiring transplantation [1, 2]. Studies showed that sirolimus therapy stabilized lung function, improved symptoms and quality of life [9], reduced size of AML [10], and achieved resolution of lymphatic tumors and chylous effusions [11]. For those patients with severe disease who fail to respond to mTOR inhibitor therapy, lung transplantation becomes a strong consideration [2, 12].

Precise clinical and physiologic criteria for lung transplantation in LAM have not been established. In contrast to some other lung diseases, e.g., interstitial pulmonary fibrosis, pulmonary hypertension, patients with LAM, even those requiring supplemental oxygen, are frequently comfortable at rest. Consequently, criteria based on clinical data, pulmonary function tests, exercise testing, and oxygen requirements, are usually employed [12–15]. Analysis of data from LAM patients prior to lung transplantation show that most patients had FEV1 and DLCO values under 30% predicted [12–14]. Consequently, some have suggested that FEV1 and DLCO values near 30% predicted, are an indication for evaluation for transplantation [2, 12–14]. However, these criteria have not been validated [12–14].

Grading of disease severity and monitoring of disease progression in LAM are frequently accomplished by examination of the patient, serial measurements of lung function, and imaging studies [2, 13]. These tests, however, may require patient cooperation, and may fail to uncover gas exchange abnormalities that become manifest only during exercise. Accordingly, because of these limitations, those tests are usually complemented by cardiopulmonary exercise testing [2, 13, 15].

High-resolution computed tomography (HRCT) scans of the chest are used in the diagnosis and evaluation of LAM [2, 13]. Radiologic studies, including calculations of a disease-specific radiologic score, determination of areas with lower attenuation and texture, or calculation of the percent of lung volume occupied by cysts (cyst score) have been reported to correlate with physiologic data [16–20].

The aim of this study was to grade the severity of disease by a computer-based computer tomography technique and correlate it with clinical and physiologic data in LAM patients with severe symptomatology who were either referred for lung transplantation or had undergone lung transplantation. The objective was to determine whether HRCT imaging data would complement physiologic and clinical data in supporting a recommendation for lung transplantation.

Methods

Forty-one patients are the subject of this study. Thirty-three of the 41 patients had been advised to undergo pre-transplant evaluation at several transplantation centers. The remaining eight patients had undergone lung transplantation. Nineteen patients did not complete evaluation. Two died who were waiting evaluation. Patients were selected for transplantation evaluation based on clinical data including use of oxygen, intolerance to activities of daily living, and the presence of severe disease by pulmonary function and computer tomography imaging. Once this cohort was identified, we selected a second group of 41 patients from our database who matched the cohort patients by age but had not been referred for transplantation evaluation. An essential requirement was that both the study group and control group had undergone computer tomography imaging that was suitable for measurement of cyst score.

Patients were diagnosed with LAM based on American Thoracic Society/European Respiratory Society guidelines [21, 22]. History, physical examination, pulmonary function tests, and computed tomography studies were obtained. The study was approved by the National Heart, Lung, and Blood Institute Institutional Review Board. All patients participated in LAM natural history and pathogenesis protocols (NHLBI Protocols 95-H-0186 and 96-H-0100), and provided written informed consent before enrollment and all methods were performed in accordance with the ethical guidelines and regulations.

Pulmonary function

Lung volumes, flow rates, and DLCO were measured using a Vmax Encore (Vyaire Medical, Yorba Linda, CA, USA) system, per American Thoracic Society/European Respiratory Society standards [23, 24]. In most of the patients, testing was performed on the same hospital visit as the CT examination.

Cardiopulmonary exercise testing

Patients exercised on a bicycle ergometer and used a computerized metabolic cart (Vmax 229 Cardiopulmonary Exercise System; Sensormedics, Yorba Linda, CA, USA), according to standard incremental protocols [15].

Six-minute walk test

Six-minute walk tests were performed according to the European Respiratory and American Thoracic Societies guidelines [25].
Radiologic methods
HRCT scans of the chest (GE Medical Systems, Waukesha, WI; Phillips Healthcare, Amsterdam, Netherlands; and Siemens Healthcare, Erlangen, Germany) were performed with the patients in a prone position during end inspiration at 120–140 kilovolt peak and 118–560 mA, with 1- to 2-s scanning times and 34- to 38-cm field of view [16–19]. Scans contained 9–13 slices, with slice thickness ranging from 1 to 1.25 mm at 3-cm intervals. Images were reconstructed using a lung kernel (filter) to emphasize the range of pixel values for lung tissues.

Lung segmentation and cyst detection
Cyst score is calculated based on the ratio of low-attenuation cyst volume to total lung volume. A computer-aided diagnostic system, built using C++ and MATLAB (MathWorks, Natick, MA), segments the lungs and classifies pixel blocks of tissue as cystic or non-cystic, based on image texture and threshold values (see Additional file 1). Lung segmentation is a multi-step process that first identifies lung boundaries and then excludes the trachea and blood vessels. Segmented lung regions are then divided into pixel blocks, which undergo classification as cystic or non-cystic using a committee of support-vector machines trained with radiologist input [17]. Cystic regions and total lung areas are calculated for every slice in a CT examination, summed separately, and then divided, yielding a total percent of lung volume occupied by cysts (cyst score) [16–18]. This technique represents an improvement from prior qualitative radiologic grading of LAM disease severity (mild, moderate, and severe), and has been validated in multiple other studies, showing strong correlations with pulmonary function tests in cohorts of patients with varying extent of disease [17–19] and tracking with LAM disease progression over time in individual patients [18]. An online supplement contains more specifics regarding the calculation technique.

Analysis of data
The correlation between cyst score and FEV1 and DLCO was evaluated by the Pearson correlation method. A control group of 41 patients, age-matched with the cohort referred for transplantation, were compared to the study group.

Results
Demographics
Thirty-seven of the 41 patients were White, two were African-Americans and two Asian-Americans. Five had TSC-LAM and 36 had sporadic LAM. Symptoms at the time of diagnosis were dyspnea in 21, pneumothorax in 15, hemoptysis in four, and pleural effusion in one (Table 1). Age of diagnosis for all patients was 42.5 ± 11.4 years. First symptoms occurred at the age of 39.0 ± 10.4 years. The mean age of the patients at the time of data collection was 54.9 ± 12.5 years. Patients had the initial evaluation prior to the establishment of sirolimus

Table 1  Demographic data from 41 LAM patients referred for lung transplantation

| Parameter                                      | Value          |
|-----------------------------------------------|----------------|
| Number of patients                            | 41             |
| Age at time of study                          | 54.9 ± 12.5 years |
| Age of LAM diagnosis                         | 42.5 ± 11.4 years |
| Age of first symptoms                         | 39.0 ± 10.4 years |
| Initial presentation                          |                |
| Dyspnea                                       | 21             |
| Pneumothorax                                  | 15             |
| Hemoptysis                                    | 4              |
| Pleural effusion                              | 1              |
| Cough                                         | 2              |
| Chest pain                                    | 1              |
| Abdominal pain                                | 1              |
| No symptoms                                   | 1              |
| Mode of diagnosis                             |                |
| Lung biopsy                                   | 21             |
| Abdominal mass biopsy                         | 2              |
| Characteristic lung CT findings and TSC       | 5              |
| Characteristic lung CT findings and lymphangioleiomyoma | 8          |
| Characteristic lung CT findings and angiomylipoma | 2          |
| Characteristic lung CT findings and elevated serum VEGF-D levels | 3          |
as treatment for patients with LAM; therefore, the conclusions reflect that subgroup of patients. The age of the eight patients who underwent lung transplantation was 46.3±5.4 years. Pulmonary function data for this cohort are shown in Table 2. The mean follow-up time prior to enrollment was 9.9±6 years.

The age of the control group was 54.0±12.7 years. Thirty-four patients were White, three African-American, three Asian and one Hispanic. Their age at the time of the first symptoms was 39.2±9.9 years and the age at the time of diagnosis was 42.4±10.5. Twenty-seven patients had dyspnea, 13 had pneumothorax, five had hemoptysis, one had bleeding from an angiomyolipoma, and another was asymptomatic. Twenty-one patients of the control group were diagnosed by tissue biopsy, nine had angiomyolipomas, two had TSC, two had chylous effusions, one had an elevated VEGF-D level, and six had extra-pulmonary LAM.

Prevalence of pneumothorax: chylothorax and use of supplemental oxygen on transplant and control groups

Of the 41 transplantation group patients, 20 had history of pneumothoraces of which 15 were bilateral. Seven patients had chylothorax. There was no significant difference between this group and the control group. In the control group, there was a total of 17 pneumothoraces of which seven were bilateral, and six chylous effusions (see Additional file 2: Table S1). There was a significant difference between the transplant and control group regarding the number of patients on continuous supplemental oxygen, 39 versus 9.

Table 2 Pulmonary function tests of 41 LAM patients before referral for lung transplantation

| Parameter          | Mean ± SD     |
|--------------------|---------------|
| TLC (liters)       | 4.8±1.2       |
| TLC (% predicted)  | 96.0±19       |
| FRC (liters)       | 3.2±0.9       |
| FRC (% predicted)  | 115.2±29.3    |
| RV (liters)        | 2.3±0.8       |
| RV (% predicted)   | 126.9±43.9    |
| RV/TLC ratio (%)   | 47±9          |
| FVC (liters)       | 2.4±0.8       |
| FVC (% predicted)  | 75.5±19.8     |
| FEV₁ (liters)      | 0.88±0.25     |
| FEV₁ (% predicted) | 36.4±9.1      |
| FEV₁/FVC ratio (%) | 34±10         |
| DLCO (ml/min/mmHg) | 69±2.1        |
| DLCO (% predicted) | 34.8±10.8     |

DLCO: diffusion capacity for carbon monoxide, FEV₁: forced expiratory volume in one second, FRC: functional residual capacity, FVC: forced vital capacity, RV: residual volume, TLC: total lung capacity

Cyst scores, FEV₁ and DLCO

The mean cyst score was 48.6±9.6%. The median value was 49.1% (Table 3, and Fig. 1). Cyst score values for those patients who had been transplanted, prior to transplantation, were very similar, 47.7±9.4%. Mean percent-predicted FEV₁ and DLCO for the 41 patients were 36.4±9.1 and 34.8±10.8%, respectively (Table 3, Fig. 1). For the patients who were subsequently transplanted, mean percent-predicted FEV₁ and DLCO were respectively, 29.6±10.1 and 32.7±13.6%. Cyst score distribution for the 41 patients is shown on Fig. 2, panel A. The distribution of percent-predicted FEV₁ and DLCO is shown on Fig. 2, panels B, and C.

The median time between measurement of the cyst scores and pulmonary function tests was 0.0±0.0 months. The interquartile range was 5.28 months.

Table 3 Percent cyst score and percent predicted FEV₁ and DLCO of 41 LAM patients referred for lung transplantation

|                | % Cyst score | % FEV₁ | % DLCO |
|----------------|--------------|--------|--------|
| Mean           | 48.6         | 36.4   | 34.8   |
| Median         | 49.1         | 38.9   | 37.5   |
| 25% percentile | 42.5         | 29.3   | 25.0   |
| 75% percentile | 54.9         | 43.1   | 44.0   |
| Minimum        | 28.2         | 15.6   | 15.0   |
| Maximum        | 69.9         | 53.1   | 53.0   |

Fig. 1 Box-and-whiskers plot showing percent cyst score, and corresponding percent predicted FEV₁ and DLCO from 41 LAM patients who were referred for or underwent lung transplantation (white bars), and a group of 41 patients matched by age, who were not referred for transplantation evaluation (hatched bars). The top line represents the 75% quartile and the lower line represents the 25% quartile. The line across the boxes represents the second quartile (median). The upper and lower whiskers indicate the maximum and minimum values. The patients who were referred for or underwent lung transplantation have significantly higher cyst score and lower FEV₁ and DLCO, *p<0.001

Table S1 Pulmonary function tests of 41 LAM patients before referral for lung transplantation
The correlation between cyst score and FEV\(_1\) was \(r = -0.357, p = 0.021\). For the DL\(_{CO}\), the correlation was \(r = -0.447, p = 0.003\) (Fig. 3). The correlation between FEV\(_1\) and DL\(_{CO}\) was \(r = 0.502, p < 0.001\).

Cyst score, and percent-predicted FEV\(_1\) and DL\(_{CO}\) for the LAM patient control group were respectively, 14.4 ± 8.8, 77.0 ± 19.9, and 65.3 ± 20.8% (Fig. 1). These values are significantly different from those of the transplantation cohort (\(p < 0.001\)).
Cardiopulmonary exercise tests and six-minute walk tests

Twenty-seven patients underwent an incremental bicycle exercise test within a year of having the CT scans and pulmonary function tests. Five patients exercised while receiving supplemental oxygen and the remaining 22 patients exercised on room air. Peak heart rate, 83 ± 11%, oxygen pulse, 77 ± 17%, peak oxygen uptake (VO₂max), 64 ± 16%, and work-load, 77 ± 23% were reduced. Oxygen saturation decreased from 97 ± 5 to 92 ± 5% (Table 4).

Thirteen patients who could not perform CPET underwent six-minute walk testing, four on supplemental oxygen and nine on room air. The average distance walked was 395 ± 120 m. Peak heart rate was 119 ± 19 beats/min. Oxygen saturation fell on all patients, including those receiving supplemental oxygen, from 97 ± 2 to 87 ± 6% (see Table 4).

Outcome
A total of eight patients underwent lung transplantation. Of these, three patients are alive 14.6 ± 0.5 years after transplantation. The remaining five patients expired within 5.3 ± 4.6 years after transplantation. Of the remaining 33 patients two died before transplantation, 12 underwent pre-transplantation testing, and 19 had not yet undergone pre-transplantation testing. The cause of death of the patients who were not transplanted was lung disease.

Discussion
Our study shows that LAM patients who are referred for or undergo lung transplantation have FEV₁ and especially for the DLCO values that are reduced. The distribution of FEV₁ was skewed to the right whereas the distribution of DLCO was bimodal. In fact, reductions in FEV₁ did not parallel reductions in DLCO. That is, some patients had either an FEV₁ or a DLCO above 50% predicted, which by itself would not be considered an indication for lung transplantation. Indeed, in a recent study, we reported that out of 84 pre-menopausal LAM patients, only 29 (34%), had both FEV₁ and DLCO values ≥ 70% predicted [26]. This is consistent with observations that some LAM patients present with mild impairment of flow rates, e.g., FEV₁, and an isolated reduction in DLCO. Some phenotypes, characterized by numerous small cysts tend to be associated with greater impairment in gas exchange than lung mechanics [27]. A recent study, showed that ultrasmall cysts primarily contribute to the reduction in DLco, with minimal effects on FEV₁ [28]. Patients with lower cyst burden and better FEV₁ tended to have smaller average cyst size and higher ultra-small cyst fraction [28]. Figure 4 shows ROC curves for control (% Cyst score) and all LAM patients (blue curve) and the control group and show that there is almost a perfect match of patient not requiring referred for transplantation (sensitivity). The area under the curve (AUC) shows that the correlation is almost 1. On the other hand, when we graph all LAM patients and transplanted patients (red line), the Figure shows that the chances that we can assign a patient to the transplanted base is almost 50%.

Table 4 Cardiopulmonary exercise and six-minute walk tests in 40 patients with LAM referred for lung transplantation

| Cardiopulmonary exercise test | Number subjects | 27 (% predicted) |
|-------------------------------|-----------------|-----------------|
| Peak heart rate (beats/min)   | 145 ± 24 (83 ± 11%) |
| O₂ pulse (ml/beat)            | 7.3 ± 2.1 (77 ± 17%) |
| Breathing reserve             | 24.6 ± 17.3 |
| VE/VO₂/AT                     | 41 |
| Load (watts)                  | 95 ± 34 (77 ± 23%) |
| Peak VO₂ (ml/min)             | 1075 ± 406 (64 ± 16%) |
| Resting SaO₂ (%)              | 96.7 ± 2.6 |
| Peak SaO₂ (%)                 | 92.3 ± 2.6 |
| Change SaO₂ (%)               | 4.3 ± 3.3 |

| Six minute walk test          | Number subjects | 13 |
|-------------------------------|-----------------|-------|
| Resting heart rate (beats/min)| 88 ± 10 |
| Peak heart rate (beats/min)   | 119 ± 20 |
| Supplemental O₂ (/min)        | 1.1 ± 2 |
| Distance walked (meters)      | 395 ± 120 |
| Resting SaO₂ (%)              | 97 ± 2.5 |
| Peak SaO₂ (%)                 | 86.8 ± 6.1 |
| Resting dyspnea index (Borg units) | 0.7 ± 0.8 |
| Peak dyspnea index (Borg units) | 5.2 ± 2.4 |

Data are shown as means ± SD
HR heart rate, VO₂max peak oxygen uptake, VO₂ max peak oxygen pulse, VE max minute ventilation at peak exercise, BR breathing reserve, VE/VO₂/AT ventilatory equivalent for carbon dioxide at anaerobic threshold, SaO₂ pulse oxygen saturation (%)
Cysts may not be detected by the computer-based technique, and the correlation between cyst scores and lung function is that small lung volumes in patients with LAM may have relatively normal lung parenchyma, trapping. Gopalakrishnan et al. [19], reported that treatment with sirolimus stabilized cyst score and improved lung diffusion capacity [28].

Another factor affecting the correlation between the cysts, causing lung diffusion capacity to be relatively normal. These studies, with sirolimus and this was associated with worsening of air trapping. Gopalakrishnan et al. [19], reported that treatment with sirolimus stabilized cyst score and improved lung texture in areas surrounding the cysts. These studies, altogether, suggest that cyst volumetric analysis is an important tool that complements physiologic testing. Indeed, exercise testing, which complements standard pulmonary function tests by uncovering what may be occult hypoxemia, showed that patients referred for transplantation had reduced exercise capacity, and experienced arterial desaturation during exercise (Table 4) [15].

Indications for lung transplantation evaluation in patients with LAM have not been precisely established. This is in part due to the fact that the severity of symptoms in patients with LAM at rest is highly variable and lung transplantation still has significant morbidity, expenses, and relatively low long-term survival [14, 29]. A study reported data from 12 LAM patients (age, 42 ± 8 years) who underwent lung transplantation [29]. Their mean percent predicted FEV1 and DLCO were respectively 19 ± 11, and 23.6 ± 9%. Average six-minute walk test distance was 273 ± 117 m, and all patients had exercise-induced hypoxemia. Eight patients had pulmonary hypertension. A study from Japan [14] conducted in 57 transplanted patients reported survivals of 86.7% at one year, 82.5% at three years, 73.7% at five years, and 73.7% at 10 years. However, when the 57 transplanted patients were compared with 41 patients referred for, but not transplanted, no statistically significant difference in post-registration survival between the transplanted group and the waiting group was observed: 94.7% survived at one year, 91.1% at three years, 84.9% at five years, and 73.0% at 10 years, versus 91.8%, 75.6%, 75.6%, and 33.6%, respectively, for the non-transplanted patients. Percent-predicted FEV1 and DLco in the transplanted group of patients were respectively 32.8 ± 17.0% (range = 9.1–77.5) and 24.7 ± 11.2% (range = 0.7–58.3), a broad range of values. In most studies reported in the literature, pre-transplant lung function and six-minute walk test data were respectively 24–33% predicted for the FEV1, 23–38% predicted for the DLCO and a six-minute walk test distance under 250 m [12, 30–34]. This wide range of data confirms that lung function tests alone may not accurately determine the precise timing for transplantation evaluation.

We suggest that, in contrast to FEV1 or DLCO, cyst score data seemed to have a more normal distribution because they measure the percentage of lung parenchyma occupied by cysts regardless of their size and not the severity of air flow obstruction, which may or may not be related to the number of cysts. As the accuracy and precision of its measurement improves, especially the contribution to the severity of ultra-small cysts to the severity of disease, quantification of cystic lung disease may be a better measure of severity of lung disease than either FEV1 or DLCO, and add important new information in assisting with the evaluation of LAM patients for referral for lung transplantation [28].

Conversely, other patients have markedly reduced FEV1, with CT scans showing larger cysts and with a well-preserved DLCO [27]. This mismatch could explain the poor correlation between FEV1 and DLCO (r = 0.502) in the transplant cohort studied here. We suggest that patients with larger cysts, who reportedly have a greater rate of decline in FEV1 than those with smaller cysts [27, 28], may have relatively normal lung parenchyma between the cysts, causing lung diffusion capacity to be relatively normal. Another factor affecting the correlation between cyst scores and lung function is that small lung cysts may not be detected by the computer-based technique employed in this study, but require using techniques that detect ultra-small cysts, that especially impair lung diffusion capacity [28].

Our findings are consistent with those of three prior studies [18–20]. Yao et al. [18], using similar imaging techniques reported that cyst scores stabilized during sirolimus therapy and this effect was associated with stabilization of lung function. Since all the patients evaluated here were not receiving sirolimus treatment, our conclusions should reflect that subgroup of patients. Evidence of stabilization in rate of change of cyst scores suggested that sirolimus therapy may reduce cyst size or formation of new cysts. Argula et al. [20] used a watershed algorithm to assess changes in cystic lesions in a subgroup of patients who participated in the MILES trial. They found that the number of cysts at residual volume increased in the placebo group and this was associated with worsening of air trapping. Gopalakrishnan et al. [19], reported that treatment with sirolimus stabilized cyst score and improved lung texture in areas surrounding the cysts.
Conclusions
Based on these findings, we suggest that patients on continuous supplemental oxygen, and who experience hypoxemia during exercise, have an FEV1 and DLCO around 30% predicted and cyst scores employing ultrasmall cysts techniques [28]. At or above 50%, be considered for evaluation for lung transplantation. The presence of pulmonary hypertension strengthens a recommendation for such a referral [35, 36]. Patients must be informed about long-term lung transplantation survival rates in LAM, and advised to consider lung transplantation if they judge their quality of life to be poor. Clinical, physiologic, and imaging data assist in making such a decision, but are not the most important criteria for transplantation referral [2, 15]. Patient's quality of life and willingness to consider having the procedure must be assessed prior to initiating such an evaluation. As imaging technology improves, measurement of cyst scores may serve as another useful method for grading lung disease severity in LAM patients being considered for transplantation.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12890-022-02123-7.

Additional file 1. Online Supplement on LAM Computer-Aided Diagnostic System.

Additional file 2. Comparison of Clinical, Functional, and Cyst Score (%) between Patients referred for Lung Transplantation (n=41).

Acknowledgements
Not applicable.

Author contributions
JM and AMT-D are responsible for study design, data analysis and writing of the manuscript. VG, JY, and MC, performed the computed tomography analysis. PJ-W and AMJ collected and reviewed clinical data. GP-R helped with writing of the manuscript. All authors read and approved the final manuscript.

Funding
Open Access funding provided by the National Institutes of Health (NIH).

Availability of data and materials
The datasets used and/or analysed during the current study are available upon request by the corresponding author.

Declarations
Ethics approval and consent to participate
The study was approved by the National Heart, Lung, and Blood Institute Institutional Review Board. All patients participated in LAM natural history and pathogenesis protocols (NHHLB Protocols 95-H-0186 and 96-H-0100), and provided written informed consent before enrollment and all methods were performed in accordance with the ethical guidelines and regulations.

Consent for publication
Not applicable.

Competing interests
None of the authors has any financial conflicts of interest.

Author details
1Pulmonary Branch, NHHLB, NIH, Building 10, Room 6D05, MSC 1590, Bethesda, MD 20892-1590, USA. 2Radiology and Imaging Sciences Department, NIH, Bethesda, MD 20892, USA. 3Cardiovascular Branch, NHHLB, NIH, Bethesda, MD 20892, USA.

Received: 10 January 2022 Accepted: 23 August 2022
Published online: 24 September 2022

References
1. Ryu JH, Moss J, Beck GJ, Lee JC, Brown KK, Chapman JT, et al. The NHHLB lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med. 2006;173:105–11. https://doi.org/10.1164/rccm.200409-1298oc.
2. Johnson SR, Taveira-DaSilva AM, Moss J. Lymphangioleiomyomatosis. Clin Chest Med. 2016;37:389–403. https://doi.org/10.1016/j.ccm.2016.04.002.
3. Ferrans VJ, Yu ZX, Nelson WK, Valencia JC, Tatsuguchi A, Avila NA, et al. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch. 2000;67:311–29. https://doi.org/10.1272/jjms.67.311.
4. Henske EP, Joźwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberculous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035. https://doi.org/10.1038/nrdp.2016.35.
5. Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2001;164:1537–40. https://doi.org/10.1164/ajrccm.164.8.210409.
6. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, Henske EP. Evidence that lymphangioleiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangioleiomyomatosis. Am J Hum Genet. 1998;62:810–5. https://doi.org/10.1086/301804.
7. Carsiillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA. 2000;97:6085–90. https://doi.org/10.1073/pnas.97.11.6085.
8. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:31–5. https://doi.org/10.1038/nrm3025.
9. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595–606. https://doi.org/10.1056/nejmoa110391.
10. Bissler JJ, McCormack FX, Young LR, Elving JM, Chuck G, Leonard JM, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140–51. https://doi.org/10.1056/nejmoa0863564.
11. Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med. 2011;154:797–805. https://doi.org/10.7326/0003-4819-154-12-201106210-00007.
12. Benden C, Rea F, Behr J, Corris PA, Reynaud-Gaubert M, Stern M, et al. Lung transplantation for lymphangioleiomyomatosis: the European experience. J Heart Lung Transplant. 2009;28:1–7. https://doi.org/10.1016/j.healun.2008.09.014.
13. Taveira-DaSilva AM, Moss J. Management of lymphangioleiomyomatosis. F1000Prime Rep. 2014;1:116. https://doi.org/10.12703/pn16-116.
14. Ando K, Okada Y, Akiba M, Kondo T, Kawamura T, Okumura M, et al. Respiratory failure research group of the Japanese ministry of health, labour, and welfare. Lung transplantation for lymphangioleiomyomatosis in Japan. PloS ONE. 2016;11:e0146749. https://doi.org/10.1371/journal.pone.0146749.
15. Taveira-DaSilva AM, Stylianou MP; Hedlin CJ, Kristof AS, Avila NA, Rabel A, et al. Maximal oxygen uptake and severity of disease in...
lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2003;168:1427–31. https://doi.org/10.1164/rccm.200206-593oc.

16. Yao J, Avila N, Dwyer A, Taveira-DaSilva AM, Hathaway OM, Moss J. Computer-aided grading of lymphangioleiomyomatosis (LAM) using HRCT. In: 19th international conference on pattern recognition, 2008. p. 1–4. https://doi.org/10.1109/ICPR.2008.4769091.

17. Yao J, Taveira-DaSilva AM, Collby TV, Moss J. CT grading of lung disease in lymphangioleiomyomatosis. AJR Am J Roentgenol. 2012;199:787–93. https://doi.org/10.2214/ajr.11.7888.

18. Yao J, Taveira-DaSilva AM, Jones AM, Julien-Williams P, Stylianou M, Moss J. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2014;190:1273–82. https://doi.org/10.1164/rccm.201405-0918oc.

19. Gopalakrishnan V, Yao J, Steagall WK, Avila NA, Taveira-Dasilva AM, Stylianou M, et al. Use of CT imaging to quantify progression and response to treatment in LAM. Chest. 2019;155:962–71. https://doi.org/10.1016/j.chest.2019.01.004.

20. Argula RG, Kokosi M, Lo P, Kim HJ, Ravenel JG, Meyer C, MILES Study Investigators, et al. A novel quantitative computed tomographic analysis suggests how sirolimus stabilizes progressive air trapping in lymphangi-oleiomyomatosis. Ann Am Thorac Soc. 2016;13:342–9. https://doi.org/10.1513/annalsats.201509-631oc.

21. Johnson SR, Cordier JF, Lazar R, Cottin V, Costabel U, Harari S, et al. Review panel of the ERS LAM task force, european respiratory society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010;35:14–26. https://doi.org/10.1183/09031936.00076209.

22. McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, et al. ATS/JRS Committee on Lymphangioleiomyomatosis, Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: lymphangioleiomyomatosis diagnosis and management. Am J Respir Crit Care Med. 2016;194:748–61. https://doi.org/10.1164/rccm.201607-1384rt.

23. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS task force, standardisation of spirometry. Eur Respir J. 2005;26:319–38. https://doi.org/10.1183/09031936.05.0034805.

24. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CPM, for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2014;44:1428–46. https://doi.org/10.1183/09031936.00150314.

25. Drazen JM, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2005;26:319–38. https://doi.org/10.1183/09031936.05.00034905.

26. Pechet TT, Meyers BF, Guthrie TJ, Battafarano RJ, Trulock EP, Cooper JD, et al. Lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplant. 2004;23:301–8. https://doi.org/10.1016/s1053-2498(03)00195-5.

27. Steagall WK, Glasgow CG, Hathaway OM, Avila NA, Taveira-Dasilva AM, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720–35. https://doi.org/10.1183/09031936.05.0034905.

28. Pechet TT, Meyers BF, Guthrie TJ, Battafarano RJ, Trulock EP, Cooper JD, et al. Lung transplantation for lymphangioleiomyomatosis: single-center Brazilian experience with no chylothorax. Transplant Proc. 2011;43:236–8. https://doi.org/10.1016/j.transproceed.2010.12.051.

29. Cottin V, Harari S, Humbert M, Mal H, Dorfmüller P, Jais X, et al. Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J. 2012;40:630–40. https://doi.org/10.1183/09031956.00093111.

30. Sonaglioni A, Baravelli M, Cassandro R, Torre O, Elia D, Anza C, Harari S. Hemodynamic mechanisms of exercise-induced pulmonary hypertension in patients with lymphangioleiomyomatosis: the role of exercise stress echocardiography. J Am Soc Echocardiogr. 2018;31:859–901. https://doi.org/10.1016/j.echo.2018.02.004.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

31. Kpodonu J, Massad MG, Chaer RA, Caines A, Evans A, Snow NJ, et al. The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis. Ann Am Thorac Soc. 2016;13:342–9. https://doi.org/10.1513/annalsats.201509-631oc.

32. Reynaud-Gaubert M, Mornex JF, Mal H, Treilhaut M, Dromer C, Quétant S, et al. Lung transplantation for lymphangioleiomyomatosis: the French experience. Transplantation. 2008;86:515–20. https://doi.org/10.1097/tp.0b013e31817c15df.